CEA — Carcinoembryonic Antigen (CEA, Carcinoembryonic Antigen)
CEA (carcinoembryonic antigen) oncomarker is applied for diagnosis of malignant neoplasms, predominantly of the gastrointestinal tract. Used for treatment efficacy monitoring, early recurrence detection, disease progression assessment, and metastasis detection.
What the test evaluates:
- Carcinoembryonic antigen (CEA) level in blood serum
- Tumor process activity and dynamics
- Therapy efficacy and recurrence risk
Biomaterial: Venous blood
- Draw blood fasting
- Exclude alcohol 24 hours before
- Abstain from smoking before testing
Medications:
- Chemotherapy, hormonal drugs, and anti-inflammatory agents may affect CEA level
- Inform physician of all medications taken
Recommended for:
- Diagnosis and monitoring of malignant intestinal, gastric, lung, breast, and pancreatic tumors
- Suspected GI tumors, prolonged digestion disorders, weight loss
- Patient condition assessment before and after GI tract surger
- Suspected lung tumor processes
- Comprehensive examination of patients with oncological risks"
Important: CEA level is not used as the sole diagnostic method. Results evaluated together with clinical data, instrumental methods (ultrasound, CT, MRI), and other lab studies.
Elevated CEA possible with:
- GI tract, pancreatic, and lung malignant tumors;
- liver or other organ metastatic lesion;
- benign intestinal and liver diseases;
- inflammatory processes
